<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868114</url>
  </required_header>
  <id_info>
    <org_study_id>LJCC 09-01</org_study_id>
    <secondary_id>RCA115018B</secondary_id>
    <nct_id>NCT00868114</nct_id>
  </id_info>
  <brief_title>Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer</brief_title>
  <official_title>A Phase II Study of Apoptosis Induction Through Direct Tumor Injection of TNFerade(TM)or Radiation Alone Followed by KLH-Pulsed Autologous Dendritic Cells in Patients With Unresectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leo W. Jenkins Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leo W. Jenkins Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study uses radiation or a gene therapy agent, TNFerade in addition to a&#xD;
      dendritic cell vaccine in patients with locally advanced or low volume metastatic pancreatic&#xD;
      cancer. The use of TNFerade or radiation serves to generate cell death stimulating the immune&#xD;
      response. The dendritic cell vaccine may direct a distant and lasting effective anti-tumor&#xD;
      immune response to achieve a local and systemic clinical benefit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor recruitment&#xD;
  </why_stopped>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Patients will be followed until death</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 weekly injections of intratumoral TNFerade plus radiation and 3 weekly intratumoral injections of dendritic cell vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation Only with 3 weekly intratumoral injections of dendritic cell vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KLH-pulsed autologous dendritic cell vaccine</intervention_name>
    <description>5 X10e7 KLH-pulsed autologous dendritic cell vaccine once weekly times three weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy proven, unresectable pancreatic cancer with an intact primary tumor that is&#xD;
             accessible to direct intratumoral injection&#xD;
&#xD;
          -  Low volume metastatic disease defined as 1) radiographically occult disease discovered&#xD;
             at the time of anticipated resection or 2) no more than 4 radiographically detected&#xD;
             metastasis none of which are greater than 2 cm in greatest dimension&#xD;
&#xD;
          -  Good overall health with a Karnofsky performance status of 70% or greater&#xD;
&#xD;
          -  No evidence or history of an autoimmune dysfunction&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Agreement to initiate and complete standard treatment (chemotherapy ± radiation) for&#xD;
             pancreatic cancer at the completion of the study&#xD;
&#xD;
          -  Age equal to or greater than 18 years&#xD;
&#xD;
          -  No prior or concurrent chemotherapy&#xD;
&#xD;
          -  No previous or concurrent immunotherapy for pancreatic cancer&#xD;
&#xD;
          -  Liver enzymes ≤ 3 times upper limit of normal:&#xD;
&#xD;
          -  Tbili ≤ 3.9 (biliary stents are allowed)&#xD;
&#xD;
          -  AST ≤ 177&#xD;
&#xD;
          -  ALT ≤ 198&#xD;
&#xD;
          -  Alk phos ≤ 378&#xD;
&#xD;
          -  Adequate pretreatment organ function:&#xD;
&#xD;
               -  Creatinine no greater than 1.5mg/dL&#xD;
&#xD;
               -  Total calcium no greater than 11.0mg/dL&#xD;
&#xD;
               -  PT no greater then 14 seconds&#xD;
&#xD;
               -  PTT no greater then 40 seconds&#xD;
&#xD;
          -  Ability to give informed consent&#xD;
&#xD;
          -  Adequate baseline hematopoietic function:&#xD;
&#xD;
               -  Total white blood cell count equal to or greater than 3,000/mm3;&#xD;
&#xD;
               -  Absolute granulocyte count greater than 1,500/mm3;&#xD;
&#xD;
               -  Absolute lymphocyte count greater than 500/mm3;&#xD;
&#xD;
               -  Platelet count equal to or greater than 100,000/mm3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of XRT to primary pancreatic tumor&#xD;
&#xD;
          -  Patients with tumors that are not accessible to direct access cannot be included in&#xD;
             the study, nor will patients with poor overall health as determined by standard&#xD;
             laboratory data and performance scales&#xD;
&#xD;
          -  Prior or concurrent chemotherapy&#xD;
&#xD;
          -  Prior history (within last four weeks) of antineoplastic therapy or irradiation&#xD;
&#xD;
          -  Prior treatment with anti-tumor vaccines not allowed&#xD;
&#xD;
          -  Patients with a history of autoimmune diseases such as SLE, rheumatoid arthritis or&#xD;
             myasthenia gravis&#xD;
&#xD;
          -  A history of HIV infection, AIDS or other immunosuppressive disease state&#xD;
&#xD;
          -  Patients requiring regular corticosteroids within the past year are ineligible. There&#xD;
             must be no use of corticosteroids in the fours weeks preceding entry into the study&#xD;
&#xD;
          -  Active bacterial, fungal or viral infection&#xD;
&#xD;
          -  Active bleeding (hemoptysis, melena, etc)&#xD;
&#xD;
          -  Women who are currently pregnant or actively breast feeding. Women of childbearing&#xD;
             potential must have a negative serum pregnancy test and must use effective&#xD;
             contraception during trial participation&#xD;
&#xD;
          -  Uncontrolled or unstable medical conditions, including angina, bronchospasm,&#xD;
             hypertension, hyperglycemia, hypercalcemia and cardiac arrhythmia&#xD;
&#xD;
          -  Any medical or psychiatric illness which in the opinion of the principal investigator&#xD;
             might compromise a patient's ability to tolerate or complete treatment&#xD;
&#xD;
          -  Patients requiring anticoagulation are ineligible&#xD;
&#xD;
          -  Refusal to receive standard treatment (chemotherapy ± radiation) after the completion&#xD;
             of the protocol&#xD;
&#xD;
          -  Evidence of DVT or prior history of DVT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel E Zervos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>East Carolina University - Leo W. Jenkins Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>East Carolina University - Leo W. Jenkins Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>March 23, 2009</study_first_submitted>
  <study_first_submitted_qc>March 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2009</study_first_posted>
  <last_update_submitted>October 15, 2018</last_update_submitted>
  <last_update_submitted_qc>October 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inoperable pancreatic cancer</keyword>
  <keyword>Dendritic Cell Vaccine</keyword>
  <keyword>Locally advanced or low volume metatstatic pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

